O-GlcNAcylation of histone deacetylase-1 in hepatocellular carcinoma promotes cancer progression
O-GlcNAcylation of histone deacetylase-1 in hepatocellular carcinoma promotes cancer progression
复制标题
肝细胞癌中组蛋白脱乙酰酶 1 的 O-GlcNAc 酰化促进癌症进展
DOI:
10.1093/glycob/cww025
复制
发表时间:
2016
期刊:
影响因子:
4.3
通讯作者:
Shen Aiguo
中科院分区:
文献类型:
--
作者:
Zhu Guizhou;Tao Tao;Zhang Dongmei;Liu Xiaojuan;Qiu Huiyuan;Han LiJian;Xu Zhiwei;Xiao Ying;Cheng Chun;Shen Aiguo
Hepatocellular carcinoma (HCC) is a malignant tumor originating in the liver. Previous studies have indicated that O-GlcNAc transferase (OGT) and histone deacetylase-1 (HDAC1) play important roles in the pathogenesis of HCC. In the present study, we investigated the physical link between OGT and HDAC1. The O-GlcNAcylation of HDAC1 is overexpressed in HCC. We found that HDAC1 has two major sites of O-GlcNAcylation in its histone deacetylase domain. HDAC1 O-GlcNAcylation increases the activated phosphorylation of HDAC1, which enhances its enzyme activity. HDAC1 O-GlcNAc mutants promote the p21 transcription regulation through affecting the acetylation levels of histones from chromosome, and then influence the proliferation of HCC cells. We also found that mutants of O-GlcNAcylation site of HDAC1 affect invasion and migration of HepG2 cells. E-cadherin level is highly up-regulated in HDAC1 O-GlcNAc mutant-treated liver cancer cells, which inhibit the occurrence and development of HCC. Our findings suggest that OGT promotes the O-GlcNAc modification of HDAC1in the development of HCC. Therefore, inhibiting O-GlcNAcylation of HDAC1 may repress the progression of HCC.